Advance Capital Management Inc. Buys Shares of 287 Eli Lilly and Company (NYSE:LLY)

Advance Capital Management Inc. bought a new stake in Eli Lilly and Company (NYSE:LLY) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 287 shares of the company’s stock, valued at approximately $223,000.

Several other large investors have also recently bought and sold shares of LLY. Loomis Sayles & Co. L P increased its stake in Eli Lilly and Company by 324.2% in the third quarter. Loomis Sayles & Co. L P now owns 1,069 shares of the company’s stock valued at $574,000 after purchasing an additional 817 shares in the last quarter. Bison Wealth LLC increased its stake in Eli Lilly and Company by 13.8% in the third quarter. Bison Wealth LLC now owns 4,504 shares of the company’s stock valued at $2,420,000 after purchasing an additional 546 shares in the last quarter. Rathbones Group PLC increased its stake in Eli Lilly and Company by 28.0% in the third quarter. Rathbones Group PLC now owns 72,222 shares of the company’s stock valued at $38,793,000 after purchasing an additional 15,803 shares in the last quarter. V Square Quantitative Management LLC increased its stake in Eli Lilly and Company by 17.0% in the third quarter. V Square Quantitative Management LLC now owns 5,760 shares of the company’s stock valued at $3,094,000 after purchasing an additional 837 shares in the last quarter. Finally, Provence Wealth Management Group increased its stake in Eli Lilly and Company by 10.3% in the third quarter. Provence Wealth Management Group now owns 2,386 shares of the company’s stock valued at $1,282,000 after purchasing an additional 223 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $891.46 on Thursday. The stock has a market cap of $847.25 billion, a P/E ratio of 131.29, a P/E/G ratio of 1.94 and a beta of 0.36. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The company has a fifty day moving average price of $793.39 and a two-hundred day moving average price of $724.73. Eli Lilly and Company has a one year low of $434.34 and a one year high of $894.87.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.62 earnings per share. As a group, equities analysts predict that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 10th. Shareholders of record on Thursday, May 16th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.58%. The ex-dividend date was Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Analysts Set New Price Targets

Several brokerages have recently issued reports on LLY. DZ Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a research report on Wednesday, February 21st. Citigroup increased their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. BMO Capital Markets increased their price objective on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 1st. Finally, The Goldman Sachs Group increased their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $787.53.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the sale, the chief accounting officer now owns 7,130 shares in the company, valued at approximately $5,842,821.10. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, major shareholder Lilly Endowment Inc sold 194,978 shares of the firm’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $885.91, for a total transaction of $172,732,959.98. Following the completion of the sale, the insider now owns 97,583,810 shares in the company, valued at approximately $86,450,473,117.10. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. Insiders sold a total of 762,804 shares of company stock worth $648,109,138 over the last quarter. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.